AstraZeneca Pharma India Limited has received a final assessment order from the Income Tax department for the assessment year 2022-23, passed under Section 143(3) read with Section 144C(13) and 144(B) of the Income Tax Act, 1961. This development follows a draft order previously disclosed on March 19, 2025.

The dispute pertains to legacy transfer pricing and corporate tax issues, with proposed adjustments amounting to approximately ₹11.88 crore, excluding interest and penalty. The company intends to challenge this final assessment order before the Income-tax Appellate Tribunal (ITAT) by filing an appeal.

At this stage, the expected overall financial implications cannot be definitively determined as the matter will be suitably challenged in due course. The company has provided these details in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.